Magali Olivier

14.0k total citations · 6 hit papers
68 papers, 9.4k citations indexed

About

Magali Olivier is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Magali Olivier has authored 68 papers receiving a total of 9.4k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 38 papers in Molecular Biology and 31 papers in Cancer Research. Recurrent topics in Magali Olivier's work include Cancer-related Molecular Pathways (43 papers), Cancer Genomics and Diagnostics (25 papers) and Epigenetics and DNA Methylation (9 papers). Magali Olivier is often cited by papers focused on Cancer-related Molecular Pathways (43 papers), Cancer Genomics and Diagnostics (25 papers) and Epigenetics and DNA Methylation (9 papers). Magali Olivier collaborates with scholars based in France, United States and United Kingdom. Magali Olivier's co-authors include Pierre Hainaut, Monica Hollstein, Audrey Petitjean, Rosalind A. Eeles, Curtis C. Harris, Shunsuke Kato, Chikashi Ishioka, Sean V. Tavtigian, Maria Isabel Achatz and Ewy A. Mathé and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Nature reviews. Cancer.

In The Last Decade

Magali Olivier

68 papers receiving 9.3k citations

Hit Papers

TP53 Mutations in Human Cancers: Origins, Consequences, a... 2002 2026 2010 2018 2009 2007 2002 2002 2007 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use
    2009 1.5k citations Magali Olivier, Monica Hollstein et al. Cold Spring Harbor Perspectives in Biology profile →
  2. Impact of mutant p53 functional properties onTP53mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database
    2007 1.2k citations Audrey Petitjean, Ewy A. Mathé et al. Human Mutation profile →
  3. The IARC TP53 database: New online mutation analysis and recommendations to users
    2002 980 citations Magali Olivier, Monica Hollstein et al. Human Mutation profile →
  4. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers
    2002 815 citations Gerd P. Pfeifer, Mikhail F. Denissenko et al. Oncogene profile →
  5. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes
    2007 689 citations Audrey Petitjean, Maria Isabel Achatz et al. Oncogene profile →
  6. TP53Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data
    2016 536 citations Maude Ardin, Monica Hollstein et al. Human Mutation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Magali Olivier France 37 5.6k 5.1k 3.2k 1.3k 1.0k 68 9.4k
Chikashi Ishioka Japan 47 5.0k 0.9× 4.3k 0.8× 2.0k 0.6× 1.0k 0.8× 1.0k 1.0× 243 8.5k
Göran Landberg Sweden 58 5.6k 1.0× 4.5k 0.9× 3.0k 0.9× 1.3k 1.0× 1.2k 1.2× 211 10.2k
Cheryl Gillett United Kingdom 45 4.2k 0.8× 4.0k 0.8× 2.4k 0.8× 1.2k 0.9× 955 0.9× 123 8.5k
Christophe Ginestier France 43 7.2k 1.3× 8.2k 1.6× 4.3k 1.3× 1.3k 1.0× 969 1.0× 94 12.8k
Brigitte Bressac–de Paillerets France 43 3.7k 0.7× 3.5k 0.7× 2.1k 0.7× 785 0.6× 1.5k 1.5× 120 7.5k
Louis Vermeulen Netherlands 44 5.5k 1.0× 7.1k 1.4× 3.3k 1.0× 1.2k 0.9× 990 1.0× 130 11.5k
Steven de Jong Netherlands 53 5.2k 0.9× 3.3k 0.7× 1.9k 0.6× 1.0k 0.8× 506 0.5× 188 9.1k
J. Dirk Iglehart United States 57 5.5k 1.0× 4.8k 0.9× 3.2k 1.0× 1.2k 1.0× 1.9k 1.9× 138 10.8k
C C Harris United States 35 5.6k 1.0× 5.4k 1.0× 2.6k 0.8× 986 0.8× 778 0.8× 65 9.9k
Todd Waldman United States 39 8.0k 1.4× 5.7k 1.1× 2.0k 0.6× 997 0.8× 696 0.7× 66 10.9k

Countries citing papers authored by Magali Olivier

Since Specialization
Citations

This map shows the geographic impact of Magali Olivier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Magali Olivier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Magali Olivier more than expected).

Fields of papers citing papers by Magali Olivier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Magali Olivier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Magali Olivier. The network helps show where Magali Olivier may publish in the future.

Co-authorship network of co-authors of Magali Olivier

This figure shows the co-authorship network connecting the top 25 collaborators of Magali Olivier. A scholar is included among the top collaborators of Magali Olivier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Magali Olivier. Magali Olivier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Andrade, Kelvin C. de, Chimene Kesserwan, James J. Manfredi, et al.. (2022). The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute. Cell Death and Differentiation. 29(5). 1071–1073. 80 indexed citations
2.
Cree, Ian A., Jiří Zavadil, James McKay, et al.. (2020). The International Collaboration for Cancer Classification and Research. International Journal of Cancer. 148(3). 560–571. 35 indexed citations
3.
Fortuño, Cristina, Paul A. James, Erin L. Young, et al.. (2018). Improved, ACMG-compliant, in silico prediction of pathogenicity for missense substitutions encoded by TP53 variants. Human Mutation. 39(8). 1061–1069. 27 indexed citations
4.
Ardin, Maude, Annette Weninger, Sarah Barrin, et al.. (2017). Modeling cancer driver events in vitro using barrier bypass-clonal expansion assays and massively parallel sequencing. Oncogene. 36(43). 6041–6048. 8 indexed citations
5.
Huang, Mi, Willie Yu, Maude Ardin, et al.. (2017). Genome-scale mutational signatures of aflatoxin in cells, mice, and human tumors. Genome Research. 27(9). 1475–1486. 75 indexed citations
6.
Tissot, Claire, Anne‐Claire Toffart, Stéphanie Villar, et al.. (2015). Circulating free DNA concentration is an independent prognostic biomarker in lung cancer. European Respiratory Journal. 46(6). 1773–1780. 99 indexed citations
7.
Villar, Stéphanie, et al.. (2015). Intérêts de l’ADN circulant pour la prise en charge du cancer broncho-pulmonaire. Revue de Pneumologie Clinique. 72(1). 61–71. 1 indexed citations
8.
Sagné, Corinne, Virginie Marcel, Maria Bota, et al.. (2013). Age at cancer onset in germline TP53 mutation carriers: association with polymorphisms in predicted G-quadruplex structures. Carcinogenesis. 35(4). 807–815. 30 indexed citations
9.
Scoccianti, Chiara, Aurélien Vesin, Magali Olivier, et al.. (2012). Prognostic value ofTP53,KRASandEGFRmutations in nonsmall cell lung cancer: the EUELC cohort. European Respiratory Journal. 40(1). 177–184. 82 indexed citations
10.
Olivier, Magali, Monica Hollstein, Heinz H. Schmeiser, Kurt Straíf, & Christopher P. Wild. (2012). Upper urinary tract urothelial cancers: where it is A:T. Nature reviews. Cancer. 12(8). 503–504. 19 indexed citations
11.
Silva, Edaise M. da, Maria Isabel Achatz, Ghyslaine Martel‐Planche, et al.. (2011). TP53 mutation p.R337H in gastric cancer tissues of a 12-year-old male child - evidence for chimerism involving a common mutant founder haplotype: case report. BMC Cancer. 11(1). 449–449. 6 indexed citations
12.
Fernandez‐Cuesta, Lynnette, Suresh Anaganti, Pierre Hainaut, & Magali Olivier. (2010). p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines. International Journal of Cancer. 128(8). 1813–1821. 30 indexed citations
13.
Anaganti, Suresh, Lynnette Fernandez‐Cuesta, Anita Langerød, Pierre Hainaut, & Magali Olivier. (2010). p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines. Cancer Letters. 300(2). 215–224. 20 indexed citations
14.
Fernandez‐Cuesta, Lynnette, Suresh Anaganti, Pierre Hainaut, & Magali Olivier. (2010). Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines. Breast Cancer Research and Treatment. 125(1). 35–42. 30 indexed citations
15.
Palmero, Edenir Inêz, Maria Isabel Achatz, Patrícia Ashton‐Prolla, Magali Olivier, & Pierre Hainaut. (2009). Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Current Opinion in Oncology. 22(1). 64–69. 64 indexed citations
16.
Olivier, Magali, Monica Hollstein, & Pierre Hainaut. (2009). TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use. Cold Spring Harbor Perspectives in Biology. 2(1). a001008–a001008. 1507 indexed citations breakdown →
17.
Petitjean, Audrey, Ewy A. Mathé, Shunsuke Kato, et al.. (2007). Impact of mutant p53 functional properties onTP53mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Human Mutation. 28(6). 622–629. 1233 indexed citations breakdown →
18.
Mathé, Ewy A., Magali Olivier, Shunsuke Kato, et al.. (2006). Predicting the transactivation activity of p53 missense mutants using a four-body potential score derived from Delaunay tessellations. Human Mutation. 27(2). 163–172. 19 indexed citations
19.
Maurici, Daniela, et al.. (2004). The Tumor Suppressor Gene TP53: Implications for Cancer Management and Therapy. Critical Reviews in Clinical Laboratory Sciences. 41(5-6). 551–583. 31 indexed citations
20.
Pfeifer, Gerd P., Mikhail F. Denissenko, Magali Olivier, et al.. (2002). Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 21(48). 7435–7451. 815 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chikashi Ishioka Breakdown of academic impact, for papers by Göran Landberg Breakdown of academic impact, for papers by Cheryl Gillett Breakdown of academic impact, for papers by Christophe Ginestier Breakdown of academic impact, for papers by Brigitte Bressac–de Paillerets Breakdown of academic impact, for papers by Louis Vermeulen Breakdown of academic impact, for papers by Steven de Jong Breakdown of academic impact, for papers by J. Dirk Iglehart Breakdown of academic impact, for papers by C C Harris Breakdown of academic impact, for papers by Todd Waldman
Rankless by CCL
2026